vs
Eventbrite, Inc.（EB）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是Eventbrite, Inc.的1.3倍（$92.9M vs $73.5M），Vericel Corp净利率更高（25.0% vs -11.1%，领先36.1%），Vericel Corp同比增速更快（23.3% vs -3.9%），Vericel Corp自由现金流更多（$12.8M vs $-60.9M），过去两年Vericel Corp的营收复合增速更高（34.6% vs -7.7%）
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
EB vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.3倍
$73.5M
营收增速更快
VCEL
高出27.1%
-3.9%
净利率更高
VCEL
高出36.1%
-11.1%
自由现金流更多
VCEL
多$73.7M
$-60.9M
两年增速更快
VCEL
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.5M | $92.9M |
| 净利润 | $-8.2M | $23.2M |
| 毛利率 | 68.1% | 78.7% |
| 营业利润率 | -12.4% | 24.1% |
| 净利率 | -11.1% | 25.0% |
| 营收同比 | -3.9% | 23.3% |
| 净利润同比 | 2.5% | 17.3% |
| 每股收益（稀释后） | $-0.08 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBVCEL
| Q4 25 | $73.5M | $92.9M | ||
| Q3 25 | $71.7M | $67.5M | ||
| Q2 25 | $72.8M | $63.2M | ||
| Q1 25 | $73.8M | $52.6M | ||
| Q4 24 | $76.5M | $75.4M | ||
| Q3 24 | $77.8M | $57.9M | ||
| Q2 24 | $84.6M | $52.7M | ||
| Q1 24 | $86.3M | $51.3M |
净利润EBVCEL
| Q4 25 | $-8.2M | $23.2M | ||
| Q3 25 | $6.4M | $5.1M | ||
| Q2 25 | $-2.1M | $-553.0K | ||
| Q1 25 | $-6.6M | $-11.2M | ||
| Q4 24 | $-8.4M | $19.8M | ||
| Q3 24 | $-3.8M | $-901.0K | ||
| Q2 24 | $1.1M | $-4.7M | ||
| Q1 24 | $-4.5M | $-3.9M |
毛利率EBVCEL
| Q4 25 | 68.1% | 78.7% | ||
| Q3 25 | 67.9% | 73.5% | ||
| Q2 25 | 67.5% | 73.7% | ||
| Q1 25 | 66.9% | 69.0% | ||
| Q4 24 | 68.2% | 77.6% | ||
| Q3 24 | 68.5% | 71.9% | ||
| Q2 24 | 70.9% | 69.5% | ||
| Q1 24 | 71.0% | 68.9% |
营业利润率EBVCEL
| Q4 25 | -12.4% | 24.1% | ||
| Q3 25 | -1.3% | 5.1% | ||
| Q2 25 | -8.7% | -3.2% | ||
| Q1 25 | -13.2% | -24.3% | ||
| Q4 24 | -10.2% | 24.5% | ||
| Q3 24 | -11.5% | -4.3% | ||
| Q2 24 | -7.6% | -11.5% | ||
| Q1 24 | -8.8% | -10.7% |
净利率EBVCEL
| Q4 25 | -11.1% | 25.0% | ||
| Q3 25 | 8.9% | 7.5% | ||
| Q2 25 | -2.9% | -0.9% | ||
| Q1 25 | -9.0% | -21.4% | ||
| Q4 24 | -11.0% | 26.3% | ||
| Q3 24 | -4.8% | -1.6% | ||
| Q2 24 | 1.3% | -8.9% | ||
| Q1 24 | -5.2% | -7.5% |
每股收益（稀释后）EBVCEL
| Q4 25 | $-0.08 | $0.46 | ||
| Q3 25 | $0.06 | $0.10 | ||
| Q2 25 | $-0.02 | $-0.01 | ||
| Q1 25 | $-0.07 | $-0.23 | ||
| Q4 24 | $-0.09 | $0.40 | ||
| Q3 24 | $-0.04 | $-0.02 | ||
| Q2 24 | $0.01 | $-0.10 | ||
| Q1 24 | $-0.05 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.9M | $137.5M |
| 总债务越低越好 | $144.4M | — |
| 股东权益账面价值 | $179.1M | $354.6M |
| 总资产 | $647.2M | $488.0M |
| 负债/权益比越低杠杆越低 | 0.81× | — |
8季度趋势，按日历期对齐
现金及短期投资EBVCEL
| Q4 25 | $299.9M | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | $441.5M | $116.2M | ||
| Q3 24 | $24.7M | $101.7M | ||
| Q2 24 | $56.7M | $102.5M | ||
| Q1 24 | $113.7M | $110.6M |
总债务EBVCEL
| Q4 25 | $144.4M | — | ||
| Q3 25 | $174.9M | — | ||
| Q2 25 | $241.3M | — | ||
| Q1 25 | $241.0M | — | ||
| Q4 24 | $240.7M | — | ||
| Q3 24 | $240.4M | — | ||
| Q2 24 | $358.7M | — | ||
| Q1 24 | $358.2M | — |
股东权益EBVCEL
| Q4 25 | $179.1M | $354.6M | ||
| Q3 25 | $189.1M | $321.9M | ||
| Q2 25 | $177.2M | $306.8M | ||
| Q1 25 | $173.3M | $295.5M | ||
| Q4 24 | $170.2M | $292.0M | ||
| Q3 24 | $179.8M | $257.5M | ||
| Q2 24 | $176.2M | $243.0M | ||
| Q1 24 | $184.1M | $233.9M |
总资产EBVCEL
| Q4 25 | $647.2M | $488.0M | ||
| Q3 25 | $744.6M | $453.3M | ||
| Q2 25 | $784.1M | $435.6M | ||
| Q1 25 | $812.3M | $424.6M | ||
| Q4 24 | $752.3M | $432.7M | ||
| Q3 24 | $817.4M | $390.4M | ||
| Q2 24 | $894.5M | $376.8M | ||
| Q1 24 | $952.2M | $356.7M |
负债/权益比EBVCEL
| Q4 25 | 0.81× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 2.04× | — | ||
| Q1 24 | 1.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-60.8M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $-60.9M | $12.8M |
| 自由现金流率自由现金流/营收 | -82.8% | 13.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | $17.6M | $24.7M |
8季度趋势，按日历期对齐
经营现金流EBVCEL
| Q4 25 | $-60.8M | $15.0M | ||
| Q3 25 | $36.7M | $22.1M | ||
| Q2 25 | $-17.5M | $8.2M | ||
| Q1 25 | $59.4M | $6.6M | ||
| Q4 24 | $-45.3M | $22.2M | ||
| Q3 24 | $44.6M | $10.2M | ||
| Q2 24 | $-32.3M | $18.5M | ||
| Q1 24 | $68.6M | $7.2M |
自由现金流EBVCEL
| Q4 25 | $-60.9M | $12.8M | ||
| Q3 25 | $36.6M | $19.5M | ||
| Q2 25 | $-17.5M | $81.0K | ||
| Q1 25 | $59.4M | $-7.6M | ||
| Q4 24 | $-45.3M | $8.5M | ||
| Q3 24 | $44.4M | $-9.2M | ||
| Q2 24 | $-32.4M | $1.8M | ||
| Q1 24 | $68.2M | $-6.8M |
自由现金流率EBVCEL
| Q4 25 | -82.8% | 13.8% | ||
| Q3 25 | 51.1% | 28.8% | ||
| Q2 25 | -24.1% | 0.1% | ||
| Q1 25 | 80.4% | -14.5% | ||
| Q4 24 | -59.2% | 11.2% | ||
| Q3 24 | 57.1% | -15.9% | ||
| Q2 24 | -38.3% | 3.4% | ||
| Q1 24 | 79.1% | -13.3% |
资本支出强度EBVCEL
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | 0.0% | 12.9% | ||
| Q1 25 | 0.1% | 27.0% | ||
| Q4 24 | 0.0% | 18.3% | ||
| Q3 24 | 0.2% | 33.5% | ||
| Q2 24 | 0.1% | 31.8% | ||
| Q1 24 | 0.4% | 27.3% |
现金转化率EBVCEL
| Q4 25 | — | 0.65× | ||
| Q3 25 | 5.76× | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | -30.37× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
